← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Cronos Group Inc. (CRON) 10-Year Financial Performance & Capital Metrics

CRON • • Industrial / General
HealthcareSpecialty & Generic PharmaCannabis & Hemp ProductsRecreational Cannabis Brands
AboutCronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Show more
  • Revenue $118M +34.8%
  • EBITDA -$67M +12.4%
  • Net Income $41M +155.5%
  • EPS (Diluted) 0.11 +157.9%
  • Gross Margin 21.42% +56.9%
  • EBITDA Margin -57.13% +35.0%
  • Operating Margin -65.07% +33.1%
  • Net Margin 34.93% +141.2%
  • ROE 3.72% +156.3%
  • ROIC -16.79% -6.9%
  • Debt/Equity 0.00 -22.0%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong 5Y sales CAGR of 37.7%
  • ✓Trading at only 0.9x book value

✗Weaknesses

  • ✗Profits declining 48.8% over 5 years
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y37.71%
3Y22.13%
TTM19%

Profit (Net Income) CAGR

10Y-
5Y-48.79%
3Y-
TTM176.09%

EPS CAGR

10Y-
5Y-56.62%
3Y-
TTM120.3%

ROCE

10Y Avg-10.15%
5Y Avg-11.02%
3Y Avg-7.81%
Latest-6.91%

Peer Comparison

Recreational Cannabis Brands
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CRONCronos Group Inc.991.69M2.5923.5534.82%27.27%3.19%0.57%0.00
CGCCanopy Growth Corporation460.99M1.22-0.22-9.47%-138.49%-52.42%0.72
SNDLSNDL Inc.417.15M1.62-4.301.26%-9.7%-8.39%10.52%0.13
OGIOrganigram Global Inc.213.79M1.59-11.3616.42%-13.3%-9.88%0.03

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+3.4M412.32K3.25M12.12M23.75M46.72M64.56M86.75M87.24M117.61M
Revenue Growth %6.12%-0.88%6.87%2.73%0.96%0.97%0.38%0.34%0.01%0.35%
Cost of Goods Sold+144.98K-1.07M1.98M5.91M41.35M72.55M82.15M71.31M75.33M92.42M
COGS % of Revenue0.04%-2.6%0.61%0.49%1.74%1.55%1.27%0.82%0.86%0.79%
Gross Profit+2.5M1.48M1.27M6.21M-17.6M-25.83M-17.59M15.44M11.91M25.2M
Gross Margin %0.74%3.6%0.39%0.51%-0.74%-0.55%-0.27%0.18%0.14%0.21%
Gross Profit Growth %78.88%-0.41%-0.14%3.9%-3.83%-0.47%0.32%1.88%-0.23%1.12%
Operating Expenses+1.55M1.48M7.43M26.66M135.72M193.55M274.38M126.86M96.71M101.73M
OpEx % of Revenue0.45%3.6%2.29%2.2%5.71%4.14%4.25%1.46%1.11%0.86%
Selling, General & Admin1.47M2.78M7M24.04M116.15M130.32M121.68M100.73M80.93M76.82M
SG&A % of Revenue0.43%6.75%2.16%1.98%4.89%2.79%1.88%1.16%0.93%0.65%
Research & Development0001.73M12.15M20.37M21.84M13.13M5.84M4.23M
R&D % of Revenue---0.14%0.51%0.44%0.34%0.15%0.07%0.04%
Other Operating Expenses0-1.3M417K807K7.42M42.87M130.85M13.01M9.93M20.68M
Operating Income+540.34K-1.23M-6.12M-20.45M-153.32M-219.39M-291.97M-111.43M-84.8M-76.53M
Operating Margin %0.16%-2.97%-1.89%-1.69%-6.46%-4.7%-4.52%-1.28%-0.97%-0.65%
Operating Income Growth %1.18%-3.27%-4%-2.34%-6.5%-0.43%-0.33%0.62%0.24%0.1%
EBITDA+622K-940.24K-5.33M-18.51M-149.04M-212.34M-276.57M-98.31M-76.69M-67.19M
EBITDA Margin %0.18%-2.28%-1.64%-1.53%-6.28%-4.55%-4.28%-1.13%-0.88%-0.57%
EBITDA Growth %1.21%-2.51%-4.67%-2.47%-7.05%-0.42%-0.3%0.64%0.22%0.12%
D&A (Non-Cash Add-back)81.66K284.76K792.05K1.94M4.27M7.04M15.4M13.12M8.11M9.34M
EBIT446.64K-1.14M-6.12M-20.78M1.17B-73.09M-165.53M-104.39M-79.91M-59.55M
Net Interest Income+-295K-173K-97K81K-4.34M18.41M9.04M22.5M51.23M52.02M
Interest Income003.2K028.62M18.6M9.07M22.51M51.23M52.02M
Interest Expense325.17K177.27K100.2K78.56K32.96M186K27K13K00
Other Income/Expense-345K277.51K3.78M-478K1.32B146.11M163.46M-9.57M11.13M113.11M
Pretax Income+215.17K-1.31M-2.35M-20.92M1.17B-73.27M-128.51M-121M-73.67M36.59M
Pretax Margin %0.06%-3.17%-0.72%-1.73%49.09%-1.57%-1.99%-1.39%-0.84%0.31%
Income Tax+-123K-423K236.98K001.35M-431K34.17M-3.23M-3.44M
Effective Tax Rate %1.29%0.68%0.63%1.03%1%1%3.08%1.39%1%1.12%
Net Income+278.28K-885K-1.48M-21.64M1.17B-73.14M-396.11M-168.73M-73.96M41.08M
Net Margin %0.08%-2.15%-0.46%-1.79%49.12%-1.57%-6.14%-1.95%-0.85%0.35%
Net Income Growth %1.07%-4.18%-0.68%-13.59%54.92%-1.06%-4.42%0.57%0.56%1.56%
Net Income (Continuing)386.17K-885K-1.48M-20.92M1.17B-74.62M-128.08M-155.18M-70.44M40.02M
Discontinued Operations00000-650K-269.13M-13.56M-4.11M0
Minority Interest00099.85K-853K-3.2M-2.97M-2.92M-3.45M46.92M
EPS (Diluted)+0.01-0.01-0.01-0.087.16-0.21-1.07-0.45-0.190.11
EPS Growth %1.05%-0.12%-7.08%89.61%-1.03%-4.1%0.58%0.58%1.58%
EPS (Basic)0.01-0.01-0.01-0.087.92-0.21-1.07-0.45-0.190.11
Diluted Shares Outstanding43.69M78.25M176.79M172.27M342.81M351.58M370.39M376.96M380.96M385.56M
Basic Shares Outstanding38.62M59.5M134.8M179.69M310.07M351.58M370.39M376.96M403.4M382.06M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+882.82K6.02M21.24M47.77M1.57B1.37B1.08B960.16M933.31M936.11M
Cash & Short-Term Investments812.39K2.58M7.32M23.96M1.51B1.29B1B877.72M861.53M858.8M
Cash Only812.39K2.58M7.32M23.96M1.2B1.08B886.97M764.64M669.29M858.8M
Short-Term Investments0000306.35M211.77M117.68M113.08M192.24M0
Accounts Receivable0107K1.14M5.79M16.53M26.04M33.29M31.29M35.88M29.77M
Days Sales Outstanding-94.72128.51174.32254.1203.47188.22131.67150.1192.39
Inventory02.76M9.65M15.17M38.04M44M32.8M37.56M30.5M33.15M
Days Inventory Outstanding--938.971.78K937.03335.83221.37145.74192.24147.75130.92
Other Current Assets0309K3.72M14.55M3.25M1.18M07.11M5.41M14.39M
Total Non-Current Assets+9.73M25.9M59.11M143.94M517.18M553.51M318.02M252.85M206.96M230.07M
Property, Plant & Equipment1.95M10.51M44.67M126.2M166.49M197.38M82.95M62.83M60.82M134.58M
Fixed Asset Turnover1.75x0.04x0.07x0.10x0.14x0.24x0.78x1.38x1.43x0.87x
Goodwill282.48K1.33M1.43M1.32M214.49M179.52M1.1M1.03M1.06M63.45M
Intangible Assets1.16M8.34M8.91M8.25M71.23M69.72M18.08M26.7M21.08M11.13M
Long-Term Investments6.34M5.72M4.1M3.08M557K19.23M135.16M89.75M54.74M2.81M
Other Non-Current Assets0005.1M64.4M87.66M80.73M72.54M69.04M15.53M
Total Assets+10.61M31.92M80.34M191.71M2.09B1.93B1.4B1.21B1.14B1.17B
Asset Turnover0.32x0.01x0.04x0.06x0.01x0.02x0.05x0.07x0.08x0.10x
Asset Growth %0.24%2.01%1.52%1.39%9.9%-0.08%-0.27%-0.13%-0.06%0.02%
Total Current Liabilities+1.68M5.78M6.26M33.4M332.89M206.83M54.37M68.12M41.4M49.7M
Accounts Payable765.29K586K6.26M1.6M35.3M19.35M11.11M11.16M12.13M16.97M
Days Payables Outstanding1.93K-199.711.16K98.67311.6397.3349.3757.1458.7767.03
Short-Term Debt767.46K2.98M015.38M000000
Deferred Revenue (Current)0000000000
Other Current Liabilities04.2M028.43M297.16M163.41M14.38M15K102K40K
Current Ratio0.53x1.04x3.39x1.43x4.73x6.63x19.86x14.10x22.54x18.84x
Quick Ratio0.53x0.56x1.85x0.98x4.61x6.42x19.25x13.54x21.81x18.17x
Cash Conversion Cycle--644.54753.631.01K278.31327.51284.58266.77239.09156.27
Total Non-Current Liabilities+500.83K1.08M5.39M2.93M8.52M10.68M9.09M3.93M2.74M5.63M
Long-Term Debt360.31K04.27M0000000
Capital Lease Obligations00006.68M8.49M7.09M2.55M1.56M993K
Deferred Tax Liabilities140.52K1.08M1.13M1.36M0081K0181K3.56M
Other Non-Current Liabilities001.13M1.57M1.84M2.19M1.91M1.38M1M1.07M
Total Liabilities2.18M6.86M11.66M36.33M341.41M217.51M63.46M72.05M44.14M55.33M
Total Debt+1.13M2.98M4.27M15.38M7.11M9.81M9.81M3.88M2.55M2.02M
Net Debt315.39K398.63K-3.05M-8.58M-1.19B-1.07B-877.17M-760.77M-666.74M-856.79M
Debt / Equity0.13x0.12x0.06x0.10x0.00x0.01x0.01x0.00x0.00x0.00x
Debt / EBITDA1.81x---------
Net Debt / EBITDA0.51x---------
Interest Coverage1.66x-6.91x-61.09x-260.25x-4.65x-1179.50x-10813.67x-8571.38x--
Total Equity+8.43M25.06M68.68M155.39M1.75B1.71B1.33B1.14B1.1B1.11B
Equity Growth %0.06%1.97%1.74%1.26%10.26%-0.02%-0.22%-0.14%-0.04%0.01%
Book Value per Share0.190.320.390.905.104.863.603.032.882.88
Total Shareholders' Equity8.43M25.06M68.68M155.29M1.75B1.71B1.34B1.14B1.1B1.06B
Common Stock10.67M24.99M66.45M165.56M561.16M569.26M595.5M611.32M662.17M669.88M
Retained Earnings-3.62M-4.62M-2.96M-16.68M1.14B1.06B659.42M490.68M416.72M457.71M
Treasury Stock0000000000
Accumulated OCI598.65K1.18M699.8K682.8K27.84M43M49.87M-797K20.68M-63.52M
Minority Interest00099.85K-853K-3.2M-2.97M-2.92M-3.45M46.92M

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-992.64K-4.82M-4.41M-7.15M-130.01M-144.87M-153.62M-88.95M-42.84M18.84M
Operating CF Margin %-0.29%-11.68%-1.36%-0.59%-5.47%-3.1%-2.38%-1.03%-0.49%0.16%
Operating CF Growth %0.31%-3.85%0.08%-0.62%-17.18%-0.11%-0.06%0.42%0.52%1.44%
Net Income278.28K-885.4K1.98M-14.1M1.17B-75.27M-397.2M-168.73M-74.55M40.02M
Depreciation & Amortization81.66K284.76K792.05K1.84M3.91M7.04M15.4M13.12M8.11M9.34M
Stock-Based Compensation0228.27K1.48M3.11M11.62M15.36M10.15M15.12M8.77M8.7M
Deferred Taxes-123.23K-422.59K236.98K359.02K-1.26B1.35M0000
Other Non-Cash Items266.75K-429.9K-3.99M-1.85M4.63M-85.7M222.88M35.89M41.31M-38.9M
Working Capital Changes424.29K-3.59M-4.91M3.48M-54.21M-7.65M-4.84M15.66M-26.47M-311K
Change in Receivables0-42.05K-821.47K-2.22M-5.41M-10.02M-12.16M-8.55M-6.59M-917K
Change in Inventory0-1.22M-6.71M-3.89M29.44M-735K11.56M-7.22M7.4M5.28M
Change in Payables340.35K-2.04M5.33M5.49M13.79M-2.78M-1.6M-863K-773K-7.45M
Cash from Investing+-1.05M-5.96M-30.83M-89.19M-603.54M20.15M-28.9M-1.84M-59.5M175.15M
Capital Expenditures-1.09M-1.13M-33.96M-84.26M-38.95M-31.41M-11.14M-3.45M-2.5M-12.52M
CapEx % of Revenue0.32%2.75%10.46%6.95%1.64%0.67%0.17%0.04%0.03%0.11%
Acquisitions----------
Investments----------
Other Investing36.03K-258.02K-2.06M-5.1M-58.32M-43.84M-3.06M4.12M18.41M8.41M
Cash from Financing+2.28M16.82M39.81M113.54M1.86B-3.05M-13.44M-2.9M-1.03M-1.23M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing-8.84K15.2M37.87M-4.98M1.87B-637K-13.44M-2.9M-1.03M-1.23M
Net Change in Cash----------
Free Cash Flow+-2.08M-5.95M-38.37M-91.41M-168.96M-180.26M-165.88M-93.98M-46.26M5.69M
FCF Margin %-0.61%-14.43%-11.82%-7.54%-7.11%-3.86%-2.57%-1.08%-0.53%0.05%
FCF Growth %0.13%-1.86%-5.45%-1.38%-0.85%-0.07%0.08%0.43%0.51%1.12%
FCF per Share-0.05-0.08-0.22-0.53-0.49-0.51-0.45-0.25-0.120.01
FCF Conversion (FCF/Net Income)-3.57x5.44x2.98x0.33x-0.11x1.98x0.39x0.53x0.58x0.46x
Interest Paid0000000000
Taxes Paid000000892K177K33.01M647K

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)3.39%-5.29%-3.16%-19.31%122.51%-4.23%-26.04%-13.63%-6.61%3.72%
Return on Invested Capital (ROIC)5.03%-5.37%-10.08%-14.44%-32.7%-27.51%-39.92%-19.96%-15.71%-16.79%
Gross Margin73.57%359.67%39.09%51.26%-74.09%-55.29%-27.25%17.79%13.65%21.42%
Net Margin8.17%-214.64%-45.69%-178.5%4911.6%-156.55%-613.54%-194.51%-84.78%34.93%
Debt / Equity0.13x0.12x0.06x0.10x0.00x0.01x0.01x0.00x0.00x0.00x
Interest Coverage1.66x-6.91x-61.09x-260.25x-4.65x-1179.50x-10813.67x-8571.38x--
FCF Conversion-3.57x5.44x2.98x0.33x-0.11x1.98x0.39x0.53x0.58x0.46x
Revenue Growth612.03%-87.89%687.25%273.41%95.94%96.71%38.19%34.37%0.57%34.82%

Revenue by Segment

201820202021202220232024
Cannabis Flower-27.93M55.19M63.59M62.07M87.91M
Cannabis Flower Growth--97.60%15.22%-2.39%41.63%
Cannabis Extracts-18.25M18.68M27.68M24.57M29.17M
Cannabis Extracts Growth--2.34%48.16%-11.23%18.72%
Product and Service, Other-533K560K634K602K535K
Product and Service, Other Growth--5.07%13.21%-5.05%-11.13%
Dry Cannabis1.16M-----
Dry Cannabis Growth------
Other Products232K-----
Other Products Growth------
Cannabis Oils44K-----
Cannabis Oils Growth------

Revenue by Geography

201820202021202220232024
CANADA-34.54M50.29M56.23M64.7M82.44M
CANADA Growth--45.62%11.81%15.06%27.41%
ISRAEL--13.38M30.52M21.13M28.37M
ISRAEL Growth---128.14%-30.74%34.23%
Other Countries-2.69M891K-1.41M6.81M
Other Countries Growth---66.83%--384.70%
UNITED STATES-9.49M9.87M5.16M--
UNITED STATES Growth--3.99%-47.79%--

Frequently Asked Questions

Valuation & Price

Cronos Group Inc. (CRON) has a price-to-earnings (P/E) ratio of 23.5x. This is roughly in line with market averages.

Growth & Financials

Cronos Group Inc. (CRON) reported $132.4M in revenue for fiscal year 2024.

Cronos Group Inc. (CRON) grew revenue by 34.8% over the past year. This is strong growth.

Yes, Cronos Group Inc. (CRON) is profitable, generating $36.1M in net income for fiscal year 2024 (34.9% net margin).

Dividend & Returns

Cronos Group Inc. (CRON) has a return on equity (ROE) of 3.7%. This is below average, suggesting room for improvement.

Cronos Group Inc. (CRON) had negative free cash flow of $5.7M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.